Evidence map›Paper›PMID 37445990›Full record

ArticleInternational journal of molecular sciences2023

Functional and Molecular Changes in the Prefrontal Cortex of the Chronic Mild Stress Rat Model of Depression and Modulation by Acute Ketamine.

Jessica Mingardi, Elona Ndoj, Tiziana Bonifacino, Paulina Misztak, Matteo Bertoli, Luca La Via, Carola Torazza, Isabella Russo, Marco Milanese, Giambattista Bonanno and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Jessica MingardiSchool of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.ORCID 0000-0002-2363-8897
Elona NdojDepartment of Molecular and Translational Medicine, University of Brescia, 25121 Brescia, Italy.
Tiziana BonifacinoDepartment of Pharmacy, Unit of Pharmacology and Toxicology, University of Genoa, 16148 Genoa, Italy.ORCID 0000-0002-3966-9874
Paulina MisztakSchool of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.ORCID 0000-0002-7232-3162
Matteo BertoliDepartment of Molecular and Translational Medicine, University of Brescia, 25121 Brescia, Italy.
Luca La ViaDepartment of Molecular and Translational Medicine, University of Brescia, 25121 Brescia, Italy.ORCID 0000-0002-8475-1551
Carola TorazzaDepartment of Pharmacy, Unit of Pharmacology and Toxicology, University of Genoa, 16148 Genoa, Italy.
Isabella RussoDepartment of Molecular and Translational Medicine, University of Brescia, 25121 Brescia, Italy.
Marco MilaneseDepartment of Pharmacy, Unit of Pharmacology and Toxicology, University of Genoa, 16148 Genoa, Italy.ORCID 0000-0003-3384-0666
Giambattista BonannoDepartment of Pharmacy, Unit of Pharmacology and Toxicology, University of Genoa, 16148 Genoa, Italy.ORCID 0000-0003-3744-5786
Maurizio PopoliDipartimento di Scienze Farmaceutiche, Università Degli Studi di Milano, 20133 Milano, Italy.ORCID 0000-0003-4670-8664
Alessandro BarbonDepartment of Molecular and Translational Medicine, University of Brescia, 25121 Brescia, Italy.ORCID 0000-0002-1127-7764
Laura MusazziSchool of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.ORCID 0000-0003-2174-989X
University of Brescia · ITUniversity of Milano-Bicocca · ITUniversity of Genoa · ITCentro San Giovanni di Dio Fatebenefratelli · ITOspedale Policlinico San Martino · ITUniversity of Milan · ITUniversity of Pisa · IT

Funding

Fondazione Cariplo 2019-3357Ministry of Education, Universities and Research 2015HRE757_002University of Genoa PRA-2013, Prot. 9563, CUPD34G13000170005
6 · The paper itself

Abstract

Stress is a primary risk factor in the onset of neuropsychiatric disorders, including major depressive disorder (MDD). We have previously used the chronic mild stress (CMS) model of depression in male rats to show that CMS induces morphological, functional, and molecular changes in the hippocampus of vulnerable animals, the majority of which were recovered using acute subanesthetic ketamine in just 24 h. Here, we focused our attention on the medial prefrontal cortex (mPFC), a brain area regulating emotional and cognitive functions, and asked whether vulnerability/resilience to CMS and ketamine antidepressant effects were associated with molecular and functional changes in the mPFC of rats. We found that most alterations induced by CMS in the mPFC were selectively observed in stress-vulnerable animals and were rescued by acute subanesthetic ketamine, while others were found only in resilient animals or were induced by ketamine treatment. Importantly, only a few of these modifications were also previously demonstrated in the hippocampus, while most are specific to mPFC. Overall, our results suggest that acute antidepressant ketamine rescues brain-area-specific glutamatergic changes induced by chronic stress.

Indexed as

KetamineMajor Depressive DisorderAnimalsAntidepressive AgentsDepressionMalePrefrontal CortexRatsStress, PsychologicalAntidepressive AgentsKetamineanimal modelantidepressantchronic mild stressketaminemolecular mechanismprefrontal cortexRNA editing

Identifiers

PMID37445990
PMCPMC10341747
OpenAlexW4382721976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.